Aldeyra Therapeutics Inc (NASDAQ:ALDX)’s share price dropped 5.1% during trading on Wednesday . The company traded as low as $5.37 and last traded at $5.43, with a volume of 54,044 shares traded. The stock had previously closed at $5.72.

ALDX has been the topic of a number of analyst reports. Stifel Nicolaus started coverage on Aldeyra Therapeutics in a research note on Friday, July 1st. They issued a “buy” rating and a $16.00 price target on the stock. Cowen and Company reissued a “buy” rating on shares of Aldeyra Therapeutics in a research note on Tuesday, May 10th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $13.15.

The stock’s 50-day moving average is $5.77 and its 200-day moving average is $5.38. The firm’s market cap is $34.22 million.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its earnings results on Wednesday, August 10th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.03. Equities analysts anticipate that Aldeyra Therapeutics Inc will post ($1.69) EPS for the current fiscal year.

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company is focused primarily on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are caused by naturally occurring toxic chemical species known as free aldehydes.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.